Cantuzumab ravtansine

Last updated
Cantuzumab ravtansine
Ravtansine ADCs.svg
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target MUC1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Cantuzumab ravtansine (huC242-SPDB-DM4) is an antibody-drug conjugate designed for the treatment of cancers. The humanized monoclonal antibody cantuzumab (huC242) is linked to a cytotoxic agent, ravtansine (DM4). [1] It uses a more hindered disulfide linkage than cantuzumab mertansine. [2]

See also

Related Research Articles

Bivatuzumab is a humanized monoclonal antibody against CD44 v6.

<span class="mw-page-title-main">Cantuzumab mertansine</span>

Cantuzumab mertansine is an antibody-drug conjugate investigated to treat colorectal cancer and other types of cancer. It is a humanized monoclonal antibody, cantuzumab (huC242) linked to a cytotoxic agent, mertansine (DM1). It was developed by ImmunoGen.

Cantuzumab is a monoclonal antibody designed for the treatment of cancers. Also known as huC242 it binds the CanAg antigen.

DM1 can refer to

<span class="mw-page-title-main">Mertansine</span> Chemical compound

Mertansine, also called DM1, is a thiol-containing maytansinoid that for therapeutic purposes is attached to a monoclonal antibody through reaction of the thiol group with a linker structure to create an antibody-drug conjugate (ADC).

<span class="mw-page-title-main">Maitansine</span> Chemical compound

Maitansine (INN), or maytansine (USAN), is a cytotoxic agent. It inhibits the assembly of microtubules by binding to tubulin at the rhizoxin binding site.

<span class="mw-page-title-main">Lorvotuzumab mertansine</span> Chemical compound

Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate. It comprises the CD56-binding antibody, lorvotuzumab (huN901), with a maytansinoid cell-killing agent, DM1, attached using a disulfide linker, SPP.

Radretumab is an antineoplastic. Philogen, a pharmaceutical company specializing in antibody-drug conjugates, is developing it as a conjugate of Iodine-131 to an antibody which binds to fibronectin extra domain-B for treatment of Hodgkin lymphoma.

<span class="mw-page-title-main">Indatuximab ravtansine</span> Chemical compound

Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate.

<span class="mw-page-title-main">Lilotomab</span> Murine monoclonal antibody against CD37

Lilotomab is a murine monoclonal antibody against CD37, a glycoprotein which is expressed on the surface of mature human B cells. It was generated at the Norwegian Radium Hospital.

Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

ImmunoGen, Inc. is a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

Lifastuzumab vedotin is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.

Sofituzumab vedotin is a monoclonal antibody designed for the treatment of ovarian cancer.

Ravtansine is a component of several drug conjugates and may refer to:

Denintuzumab mafodotin is a humanized monoclonal antibody-drug conjugate designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent. This drug was developed by Seattle Genetics.

Depatuxizumab mafodotin is an antibody-drug conjugate designed for the treatment of cancer. It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.

Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells. It was originally developed by Stemcentrx and was purchased by AbbVie. It was tested for use in small-cell lung cancer, but development was terminated after unsuccessful phase III trial.

Cofetuzumab pelidotin is an experimental antibody-drug conjugate in development for the treatment of cancer. It was created by Stemcentrx and is being developed by Pfizer. The drug is an anti-PTK7 monoclonal antibody linked to auristatin-0101, an auristatin microtubule inhibitor.

Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. It is a combination of tisotumab, a monoclonal antibody against tissue factor, and monomethyl auristatin E (MMAE), a potent inhibitor of cell division. It is administered by infusion into a vein.

References

  1. ↑ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2). Archived from the original (PDF) on April 1, 2012.
  2. ↑ Goldmacher VS, Singh R, Chittenden T, Kovtun Y (2013). "Linker technology and impact of linker design on ADC properties.". In Phillips GL (ed.). Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications. New York: Springer. pp. 117–135 (131). ISBN   978-1-4614-5456-4.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.